Comparative Study of Cyclioxygenase-2 Expression and HER-2/neu Amplification in Korean and Caucasian Women with Early-Onset Breast Carcinoma

한국인과 백인 젊은 여성 유방암 환자에서 Cyclooxygenase-2 발현과 HER-2/neu 증폭의 비교 연구

  • Choi, Doo-Ho (Departments of Radiation Oncology, College of Medicine Soonchunhyang University) ;
  • Kim, Eun-Seog (Departments of Radiation Oncology, College of Medicine Soonchunhyang University) ;
  • Kim, Yong-Ho (Departments of Radiation Oncology, College of Medicine Soonchunhyang University) ;
  • Jin, So-Young (Departments of Pathology, College of Medicine Soonchunhyang University) ;
  • Lee, Dong-Wha (Departments of Pathology, College of Medicine Soonchunhyang University) ;
  • Haffty, Bruce G. (Department on Therapeutic Radiology, School of Medicine, Yale University)
  • 최두호 (순천향대학교 의과대학 방사선종양학과) ;
  • 김은석 (순천향대학교 의과대학 방사선종양학과) ;
  • 김용호 (순천향대학교 의과대학 방사선종양학과) ;
  • 진소영 (순천향대학교 의과대학 병리과) ;
  • 이동화 (순천향대학교 의과대학 병리과) ;
  • Published : 2004.12.01

Abstract

Purpose: The purpose of this work was to study the differences of cyclooxygenase (COX-2) expression between Korean and Caucasian patients with early-onset breast carcinoma by immunohistochemistry. The test were analyzed to find a correlation between COX-2 and other biomarkers including HER-2/neu amplification, because we previously reported that a significant difference had been found in the expression of HER-2/neu between the two races. Furthermore, we investigated prognostic significance of COX-2 in korean patients. Materials and Methods: Sixty Korean women who were diagnosed breast carcinoma at 45 years old or younger and 60 Caucasian women with breast carcinoma were selected for this study. The median age of both groups was 37 years and tumor sizes were distributed evenly between the two group. Paraffin embedded blocks of primary tumor were processed for immunohistochemical staining of COX-2. The COX-2 expression was evaluated according to the percentage of positive cells and the intensity of staining. And the results were compared with the data of the previous studies to find correlation between COX-2 and other parameters and survival data. Results: Proportion of the COX-2 expression in total patients was $27.6\%$. The percentage of tumors that stained positive for COX-2 in korean and Caucasian women with early-onset breast carcinoma were $37.9\%$ and $20.8\%$, respectively. The difference was statistically not significant(p=0.090). Expression of COX-2 was not associated with several clinicopathologic parameters including HER-2/neu overexpression, but negative estrogen receptor status was correlated with significance (p=0.046). The 5 year disease free survival rate for patients with COX-2 expression was $67.9\%$, compared to $81.9\%$ of the COX-2 negative patients and the result was statistically not significant. Conclusions : A significant difference was not found in the expression of COX-2 between the two groups of patients with early-onset breast carcinoma. And correlation between COX-2 and other parameters was not observed except estrogen receptor negativity. Large scaled further research including radiotherapy factors will be needed to identify COX-2 as a prognostic role in patients with early-onset breast carcinoma.

References

  1. Ministry of Health and Welfare. Annual report of the central cancer registry in Korea. Seoul: Ministry of Health and Welfare 2001
  2. Hunter CP. Epidemiology, stage at diagnosis, and tumor biologyof breast carcinoma in multiracial and multiethnic populations. Cancer 2000;88:1193-1202 https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D
  3. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer 2000;88:114-123 https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<114::AID-CNCR16>3.0.CO;2-J
  4. Chen VW, Correa P. Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarker Prev 1994;3:127-135
  5. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994;86:705-712 https://doi.org/10.1093/jnci/86.9.705
  6. Stanford JL, Greenberg RS. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 1989;79:71-73 https://doi.org/10.2105/AJPH.79.1.71
  7. Ownby HE, Frederick J, Russo J, et al. Racial differences in breast cancer patients. J Natl Cancer Inst 1985;75:55-60
  8. Valanis B, Wirman J, Hertzberg VS. Social and biological factors in relation to survival among black vs. white women with breast cancer. Breast Cancer Res Treat 1987;9:135-143 https://doi.org/10.1007/BF01807366
  9. Shiao YH, Chen VW, Lehmann HP, Wu XC, Correa P. Patterns of DNA ploidy and S-Phase fraction associated with breast cancer survival in blacks and whites. Clin Cancer Res 1997;3:587-592
  10. Krieger N, avn den, Eeden SK, et al. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in San Francisco bay area. Ethn Dis 1997;7:137-149
  11. Choi DH, Lee MH, Allen EB, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients. J Clin Oncol 2004;22:1638-1645 https://doi.org/10.1200/JCO.2004.04.179
  12. Choi DH, Shin DB, Lee MH, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587-1595 https://doi.org/10.1002/cncr.11703
  13. Choi DH, Lee MH, Ahn YH, et al. Characteristics of HER-2/neu oncogene in Korean Women with early-onset breast cancer by immunohistochemistry and fluorescence in situ hybridization. J Korean Breast Cancer Soc 2003;6:255-62 https://doi.org/10.4048/jkbcs.2003.6.4.255
  14. Singer-Ranger G, Mokbel K. The role of cyclooxygenase- 2 (COX-2) in breast cancer, and implications of COX-2 inhibition. European J Surg Cancer 2002:28;729-737
  15. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent Ductal Carcinoma In Situ. Cancer Research 2002:62;1676-1681
  16. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002:62;632-635
  17. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 Is overexpressed in HER-2/neu positive breasr cancer. J Biol Chem 2002:277;18649-18657
  18. Costa C, Soares R, Reis-Filho JS, et al. Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002:55;429-434
  19. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor2 (HER-2)/neu-induced breast cancer. Cancer Research 2002:62;5405-5407
  20. Spizzo G, Gas G, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. British J Cancer 2003:88; 674-578
  21. Soslow RA, Dannenberg AJ, Rush D, et al. Cyclooxygenase- 2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000;89:2637-2645 https://doi.org/10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B
  22. Parret ML, Harris RL, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997;10:503-508
  23. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival inpatients with breast carcinoma. Cancer 2003;97:2978-2987 https://doi.org/10.1002/cncr.11437
  24. Nam EM, Im SA, Kim DY, et al. Increased expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathologic prognostic factors. The 28th Annual meeting of the Korean Cancer Association 2002 abstract#23
  25. Ahn JH, Kim SB, Ahn SH, et al. Clinical value of cyclooxygenase expression in human breast carcinoma. Cancer Res Treat 2004;36:192-198 https://doi.org/10.4143/crt.2004.36.3.192
  26. Song H, Koo TY, Park JH, et al. Inhibition of cyclooxygenase- 2 expression by Genistein in breast cancer cell-line. J Korean Breast cancer Soc 2003;6:277-282 https://doi.org/10.4048/jkbcs.2003.6.4.277
  27. Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase- 2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2000;60:1326- 1331
  28. Pyo H, Shin YK, Kim HS, Seong J, Suh CO, Kim GE. The enhancement of radiosensitivity by celecoxib, selective cyclooxygenase-2 inhibitor, on human cancer cells expressing differential levels of cyclooxyganase-2. J Korean Soc Ther Radiol Oncol 2003;21;216-221
  29. Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase- 2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:16-20 https://doi.org/10.1016/S0360-3016(02)03821-X
  30. Kim JB, Wu HG, Park SW, Kim CJ, Park CI. Expression of cyclooxygenase (COX)-2 as a prognostic factor in nasopharyngeal cancer. Cancer Res Treat 2004;36:187-191 https://doi.org/10.4143/crt.2004.36.3.187
  31. O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:1034-1040 https://doi.org/10.1016/j.ijrobp.2003.08.032
  32. Benoit V, Relic B, Leval XX, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase- 2 and prostaglandin E2. Oncogene 2004;23:1631-1635 https://doi.org/10.1038/sj.onc.1207295
  33. Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M, Tari AM. Cyclooxygenase-2 is essential for HER2/ neu to suppress N-(4-Hydroyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res 2004;64:1224-1228 https://doi.org/10.1158/0008-5472.CAN-03-2188
  34. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase- 2 inhibitor, celecoxib, prevents the development of mammary tumors in HER-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003;12:1486-491
  35. Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatment. Clin Cancer Res 2004;10:4062-4067 https://doi.org/10.1158/1078-0432.CCR-03-0463